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Purpose
The aim of this study was to examine the clinical implications of a pathologically com-
plete response after neoadjuvant chemoradiotherapy (CRT) followed by local excision
for patients with cT2 rectal cancer who refused radical surgery.
Materials and Methods
Seventeen patients with cT2 primary rectal cancer within 6 cm from the anal verge
who received neoadjuvant CRT and local excision because of patient refusal of radical
surgery or poor performance status were included. Two patients had clinical involve-
ment of a regional lymph node. Preoperative radiotherapy was delivered to the whole
pelvis at a dose of 44 to 50.4 Gy in 22 to 28 fractions. All patients underwent transanal
excision and eight patients (47%) received postoperative chemotherapy.
Results
Ten patients (59%) achieved ypT0. At a median follow-up period of 75 months (range,
22 to 126 months), four (24%) patients developed recurrence (two locoregional and
two distant). The 5-year disease-free survival of all patients was 82%, and was higher
in patients with ypT0 (90%) than in patients with ypT1-2 (69%, p=0.1643). Decreased
disease-free survival was also observed in patients receiving capecitabine compared
with 5-fluorouracil (54% vs. 100%, p=0.0298). 
Conclusion
Local excision could be a feasible alternative to radical surgery in patients with ypT0
after neoadjuvant CRT for cT2 distal rectal cancer without further radical surgery.
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Introduction
Neoadjuvant chemoradiotherapy (CRT) followed by total
mesorectal excision (TME) is a standard treatment in patients
with locally advanced rectal cancer [1,2]. In addition to im-
proved local control, reduced toxicity, increased sphincter
preservation, and tumor downstaging have been demon-
strated after neoadjuvant CRT [1]. Complete pathologic re-
sponse (ypCR) of approximately 15% has been reported after
CRT [3,4]. Patients with ypCR after CRT tend to have de-
creased local or distant recurrence and improved survival [4-
6]. Some authors have reported that a wait-and-see policy
without surgical resection could be possible with strict selec-
tion criteria [7,8].
Radical surgery is associated with significant morbidity,
especially in cases of low rectal cancer [9,10], therefore, local
excision might be an alternative treatment to radical surgery
after neoadjuvant CRT in selected cT2-3 cases [11-13].
However, cautious and strict patient selection is crucial in
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this approach [14]. Higher risk of recurrence has limited the
routine application of local excision alone in cT2 rectal cancer
[15]. The incidence of local recurrence was 24% in T2 rectal
cancer after local excision alone [15]. In addition, salvage
treatment for failure after local excision is difficult and is
often associated with treatment-related morbidity [16].
Under National Comprehensive Cancer Network (NCCN)
guidelines, the standard treatment for cT2N0 rectal cancer is
radical surgery, and adjuvant treatments are recommended
according to pathological status [17]. For patients with cT2
distal rectal cancer whose sphincteric muscles cannot be pre-
served with abdominoperineal resection (APR), local exci-
sion after neoadjuvant CRT is an alternative approach to
preserving the sphincter with equivalent oncologic outcomes
[18,19]. A recent randomized clinical trial of local resection
versus TME after neoadjuvant therapy showed equivalent
disease-free survival (DFS) in patients with cT2N0, a diame-
ter no larger than 3 cm, and histological grade G1-2 rectal
cancer [20]. The probability of developing recurrence was
12% after local excision. Recurrence occurred only in low or
non-responders to neoadjuvant CRT.  
In this study, to elucidate the clinical implication of ypCR
after neoadjuvant CRT in patients with cT2 distal rectal can-
cer, the Korean Radiation Oncology Group (KROG) con-
ducted a multicenter retrospective study that examined the
DFS according to ypT status.
Materials and Methods
Seventeen patients with cT2 primary rectal adenocarci-
noma who were treated by neoadjuvant CRT and local exci-
sion between 2002 and 2009 were enrolled from four
institutions. After approval by the KROG (KROG 12-06), the
medical and radiotherapy (RT) records of the patients were
reviewed retrospectively. The median age of patients was 63
years (range, 38 to 79 years). There were 11 (65%) men and
six (35%) women. All tumors were located within 6 cm from
the anal verge as measured by digital examination. For
clinical staging, computed tomography (CT, n=15), magnetic
resonance imaging (n=8), or transrectal ultrasound (n=11)
was performed. Three patients were diagnosed by CT scan
only. When positive lymph node involvement was defined as
a lymph node ≥ 0.5 cm in the short-axis diameter, two patients
had clinical involvement of a regional lymph node. The tumor
characteristics at diagnosis are summarized in Table 1.
Patient refusal of radical surgery (n=16) and poor perform-
ance status (n=1) were the reasons for undergoing local
excision following neoadjuvant CRT. Patients who chose
local excision were fully informed about the tumor response
to neoadjuvant CRT and the options of surgical modalities
between radical resection and local excision. RT was deliv-
ered to the whole pelvis at a dose of 45 Gy in 25 fractions
(n=8), 50.4 Gy in 28 fractions (n=5), or 44 Gy in 22 fractions
(n=4) by 6-15 MV photon beams. The regimens of concurrent
chemotherapy included 5-fluorouracil (5-FU; n=9, 53%),
capecitabine (n=7, 41%), and S-1 plus irinotecan (n=1, 6%).
There was no incidence of grade 3 or higher toxicity associ-
ated with neoadjuvant CRT. The median interval between
completion of CRT and surgery was 53 days (range, 40 to 75
days). All patients underwent transanal tumor excision. Post-
operative chemotherapy was delivered to eight (47%)
patients, and six received four cycles of 5-FU.
The median follow-up duration calculated from the initia-
tion of CRT was 75 months (range, 24 to 126 months). The
primary endpoint of this study was DFS according to ypT-
classification, which was divided into ypT0 or not. DFS was
defined as the time from the initiation of the CRT to rectal
cancer relapse or death, while second primary cancers were
not included. DFS was estimated using the Kaplan-Meier
test. DFS according to ypT-classification was compared using
the log-rank test. The secondary endpoint was pattern of
disease recurrence. SAS ver. 9.1.3 (SAS Institute Inc., Cary,
NC) was used for statistical analysis. A p < 0.05 was chosen
for statistical significance.
Results
1. Surgical pathology after CRT
The primary tumor included ypT0 (n=10, 59%), ypT1 (n=6,
35%), and ypT2 (n=1, 6%). All of the ypT1-2 tumors were
adenocarcinoma. Histologic grade was well-differentiated in
one tumor, and moderately-differentiated in six tumors.
Lymphovascular invasion, perineural invasion, and involve-
ment of the resection margin were not observed. Resection
margins were not involved in pathologically residual tu-
mors, although the distances of resection margins were not
described, except two patients. There was no pathologic in-
volvement of regional lymph node (n=4). Among the seven
patients with ypT1-2 disease, five received postoperative
chemotherapy, while three of the 10 patients with ypT0
received adjuvant chemotherapy. The clinicopathologic char-
acteristics according to ypT-classification are summarized in
Table 2.
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CRT, chemoradiotherapy; CEA, carcinoembrynonic antigen; 5-FU, 5-fluorouracil.
Table 2. Clinicopathologic characteristics according to ypT-classification
Characteristic ypT0 (n=10) ypT1-2 (n=7)
Gender
Male 6 5
Female 4 2
Median age (yr) 64 (38-79) 53 (41-64)
Median pre-CRT CEA (ng/mL) 1.4 (0.8-4.5) 1.1 (0.7-30.6)
Median post-CRT CEA (ng/mL) 1.1 (0.5-5.0) 1.8 (0.3-3.0)
Histologic grade (pre-CRT)
Well 2 3
Moderate 8 3
Clinical N-classification
0 10 5
1 0 2
Chemotherapy (preoperative)
5-FU 6 3
Capecitabine 4 3
S-1+irinotecan 0 1
Chemotherapy (postoperative)
5-FU (+leucovorin) 3 5
No 7 2
Table 1. Tumor characteristics at diagnosis
Characteristic No. (%)
Distance from anal verge (cm)
Median 3
Range 1-6
Histologic grade
Well 5 (29)
Moderate 11 (65)
Unknown 1 (6)
Clinical N-classification
N0 15 (88)
N1 2 (12)
Tumor size (cm)
Median 2.0
Range 1.4-4.0
Serum carcinoembryonic antigen (ng/mL)
Median 1.3
Range 0.7-30.6
2. Survival rates according to tumor response
During the follow-up period, four patients (24%) experi-
enced recurrence (Table 3). Locoregional and distance recur-
rences each occurred in two patients, respectively. Among
the patients who achieved ypT0 after neoadjuvant CRT, one
patient (10%) experienced regional recurrence after 14
months. Three (43%) out of the seven ypT1-2 patients expe-
rienced a recurrence. One patient had locoregional recur-
rence and two had distant metastasis. The 5-year DFS of all
patients was 82% (Fig. 1A). DFS in patients with ypT0 tumors
was higher than in patients with ypT1-2 tumors (90% vs.
69%) (Fig. 1B), however, the difference was not significant
(p=0.1643). Lower DFS was observed in patients who
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received capecitabine as neoadjuvant CRT, compared with
patients treated with 5-FU (54% vs. 100%, p=0.0298). Among
the seven patients with tumors close to the anal verge (< 3
cm), three patients had disease relapse (p=0.1434) (Table 4).
No significant difference in DFS was observed for other clin-
icopathologic characteristics (Table 4). None of the patients
died during the follow-up period.
Discussion
ypCR after neoadjuvant CRT is known to be associated
with favorable long-term oncologic outcomes [4-6]. Accord-
ing to results of a pooled analysis, the ypCR rate is 16% [4].
Local control, distant metastasis-free survival, DFS, and over-
all survival were favored in patients with ypCR. The
adjusted hazard ratio by Cox proportional hazards model
was 0.41 (95% confidence interval [CI], 0.21 to 0.81), 0.49 (95%
CI, 0.34 to 0.71), 0.54 (95% CI, 0.40 to 0.73), and 0.65 (95% CI,
0.47 to 0.89) for the outcomes, respectively. However, most
studies included patients with cT3 rectal cancer who under-
went radical surgery. Similar findings were observed in pa-
tients who underwent local excision following neoadjuvant
CRT for cT2-3 rectal cancer [12]. The prevalence of ypT0 was
22% (53 of 237). After local excision, none of the patients with
ypT0 experienced local recurrence, while 2%, 7%, and 21%
of patients with ypT1, ypT2, and ypT3, respectively, experi-
enced local recurrence. Although 34% of the patients had cT2
rectal cancer, the relationship between ypT-classification and
clinical outcome in cT2 disease was not evaluated. 
Cancer Res Treat. 2014;46(3):243-249
Table 3. Characteristics of patients who experienced disease recurrence
Preoperative Postoperative Site of
Age (yr) Gender AV (cm) Grade cN ypT DFS (mo)
chemotherapy chemotherapy failure
53 Male 6 Well 0 Capecitabine 1 5-FU Distant 14
49 Female 1 Well 0 Capecitabine 0 5-FU Locoregional 14
41 Female 2 Unknown 1 Capecitabine 1 5-FU Distant 43
62 Male 2 Moderate 0 5-FU 1 No Locoregional 93
AV, anal verge; DFS, disease-free survival; 5-FU, 5-fluorouracil.
Fig. 1. (A) Disease-free survival of all patients. (B) Disease-free survival according to ypT-classification.
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Table 4. Disease-free survival according to clinicopathologic characteristics
Variable No. 5-Year rate (%) p-value
Gender
Male 11 91 0.4132
Female 6 67
Age (yr)
< 60 13 76 0.3320
≥ 60 14 100
Tumor size (cm)
< 2 5 80 0.7369
≥ 2 12 81
Distance from AV (cm)
< 3 7 69 0.1434
≥ 3 10 90
Histologic grade
Well 5 60 0.2056
Moderate 11 100
Clinical N-classification
0 15 87 0.2018
1 2 100
Chemotherapya)
5-FU 9 100 0.0298
Capecitabine 7 54
ypT-classification
0 10 90 0.1643
1-2 7 69
AV, anal verge; 5-FU, 5-fluorouracil. a)The patient who received S-1 plus irinotecan was excluded from comparison.
A recent randomized trial reported equivalent DFS to TME
after local excision following neoadjuvant CRT [20]. The trial
included patients with cT2N0, histologic grades 1-2 with
tumors < 3 cm in diameter and within 6 cm of the anal verge,
similar to the current study. After local resection, ypT0 was
observed in 28% of patients, comparable to that of patients
who received TME (26%). The probability of developing dis-
ease recurrence at the end of follow-up was 12% after local
resection, and the corresponding overall survival rate was
72%. Although the duration of follow-up was shorter and the
number of patients was smaller, the rate of ypT0 (59%) and
overall survival rate were higher in the current study. In ad-
dition, the randomized trial did not evaluate the clinical im-
plication of ypT0 after local resection. In the current study,
ypCR after neoadjuvant CRT for cT2 rectal cancer showed
an association with favorable outcomes in patients who un-
derwent local excision. After neoadjuvant CRT, ypT0
showed an association with improved DFS compared with
ypT1-2 in cT2 distal rectal cancer. The small number of pa-
tients limited the power of the study, and higher rate of ypT0
might be influenced by potential selection bias, which could
be caused by patient’s choice of local excision after they were
informed about the clinical tumor response and the option
of avoidance of radical resection. However, local excision
could be a feasible alternative to radical surgery in properly
selected patients with ypCR after neoadjuvant CRT for cT2
distal rectal cancer, which is located within 6 cm of the anal
verge. 
Of particular interest, most cases of disease recurrence
occurred in patients who had received capecitabine as neoad-
juvant therapy, regardless of postoperative chemotherapy.
However, no difference in the proportion of patients with
ypCR after neoadjuvant CRT was observed between the two
chemotherapeutic regimens (67% vs. 57%, p=1). Compared
to 5-FU, oral capecitabine demonstrated comparable or im-
proved tumor response, local control, DFS, and overall sur-
vival in patients who received neoadjuvant CRT for locally
advanced rectal cancer [21,22]. In addition to the convenience
of oral administration and lesser toxicities, capecitabine has
several advantages, including preferential activation in
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tumor tissue and a synergistic effect with X-ray [23]. Oral
capecitabine is currently a valid option in neoadjuvant CRT
for rectal cancer, as investigated in previous studies [21,22].
However, most previous studies regarding local excision
following neoadjuvant CRT used 5-FU as a chemotherapeu-
tic regimen [12,13,20]. Efficacy of oral capecitabine in this set-
ting has not been well established. Whether capecitabine is
still as effective as 5-FU in patients receiving neoadjuvant
CRT followed by local excision should be clarified. However,
due to the small sample size, different DFS according to
neoadjuvant chemotherapeutic regimen in the current study
is not sufficient to answer this question. 
In the current study, most of the enrolled patients refused
radical surgery such as APR because the tumors were located
in the distal rectum. Although a meta-analysis showed no
difference in general quality of life (QoL) following APR or
anterior resection [24], a sphincter-preserving procedure is
preferred in terms of QoL for patients [25]. In this regard,
local excision combined with neoadjuvant CRT could be the
first treatment option in patients with cT2 distal rectal cancer
for whom the anal sphincter cannot be preserved. After local
excision, patients with residual tumors in the specimen
should consider radical surgery. Because local excision alone
is associated with increased risk of disease recurrence, it
should be applied cautiously to patients with residual
disease after neoadjuvant CRT.
Conclusion
In conclusion, local excision could be a feasible alternative
to radical surgery in patients with ypCR after neoadjuvant
CRT for cT2 distal rectal cancer. Future studies including a
large patient population are needed in order to confirm the
efficacy of local excision in this setting.
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